Couple welcomes world's ‘oldest baby' born from embryo frozen in 1994
Thaddeus Daniel Pierce was born to parents Lindsey and Tim Pierce on 26 July, about 31 years after his embryo was frozen.
After trying for seven years to conceive a baby, the couple from London, Ohio, chose to adopt an embryo created through IVF in 1994 by Linda Archerd, now 62 years old, and her then-husband.
"We had a rough birth, but we are both doing well now,' Lindsey Pierce told MIT Technology Review. "He is so chill. We are in awe that we have this precious baby!"
Ms Pierce said they didn't "go into it thinking we would break any records. We just wanted a baby".
The newborn is believed to have broken the record for the 'oldest' baby, which was previously held by twins born in 2022 from embryos frozen in 1992.
She said her family and church family think 'it's like something from a sci-fi movie'.
Ms Archerd created four embryos, out of which one became her daughter, now aged 30, and three others were left in storage.
Despite her separation from her husband, Ms Archerd was adamant about not discarding the embryos, donating them for research, or anonymously giving them to another family. She said it was essential for her to remain involved in the process, as the child would be a biological sibling to her adult daughter.
'It's my DNA; it came from me … and [it's] my daughter's sibling,' she told the MIT Technological Review.
She reportedly spent thousands of dollars annually on storage until she discovered Nightlight Christian Adoptions – a faith-based agency that runs the Snowflakes program. The initiative allows embryo donors to select the adoptive couple after taking into account preferences such as religion, race, and nationality.
Ms Archerd said she requested a married, Caucasian, Christian couple based in the US. "I didn't want to go out of the country," she added.
'It's been pretty surreal. It's hard to even believe," said Ms Archerd, who is yet to meet the baby.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
an hour ago
- The Independent
Trump's NASA chief Sean Duffy expedites timeline for nuclear reactor on the moon
President Donald Trump's NASA chief Sean Duffy has expedited the timeline to build a nuclear reactor on the moon, according to a directive obtained by The Independent . The space agency has already mentioned the benefits of developing fission surface power (FSP) on the moon and Mars. 'Relatively small and lightweight, fission systems are powerful and could enable robust operations on the Moon and Mars,' NASA writes on its website. The agency says it's currently working with the Energy Department and the space industry to design a fission power system that would provide at least 40 kilowatts of power. In a directive sent to the heads of NASA on July 31, Duffy, the acting administrator of the agency and Trump's transportation secretary, ordered that the nuclear reactor provide at least 100 kilowatts of power and be ready to launch by 2030. NASA chief Sean Duffy has expedited the timeline to build a nuclear reactor on the moon, according to a new directive () The directive, first reported on by Politico, mentioned China and Russia's joint effort to place a reactor on the moon by the mid-2030s. The two U.S. adversaries first announced their plans in March 2024. 'The first country to do so could potentially declare a keep-out zone which would significantly inhibit the United States from establishing a planned Artemis presence if not there first,' Duffy warned in the directive. NASA's Artemis campaign aims to establish the first long-term presence on the moon. During Trump's inaugural address, he said the U.S. would launch astronauts 'to plant the stars and stripes on the planet Mars.' 'It is about winning the second space race,' a NASA senior official told Politico. An artist's concept of a fission power system on the moon (NASA) In Duffy's new timeline, a Fission Surface Power Program Executive will be designated within 30 days of the directive. The executive 'is empowered to provide reporting and updates with maximum transparency directly to the Administrator,' Duffy wrote. Within 60 days, NASA will ask for industry proposals for the nuclear reactor, according to the directive. The directive mentioned Trump's budget request for the 2026 fiscal year, which includes $350 million for a new program 'that will accelerate the development of high priority technologies for Mars, (i.e. FSP).' The funding would increase up to $500 million starting in the 2027 fiscal year. Trump's budget request also proposes a huge cut to NASA, with The Planetary Society, a global non-profit space organization, reporting it's the smallest budget proposed for the agency since 1961.
The Independent
4 hours ago
- The Independent
Scientists identify cause of sea star epidemic along North America's Pacific coast
Scientists have identified a specific bacterium, Vibrio pectenicida, as the cause of the devastating sea star wasting disease that has killed over five billion sea stars off North America's Pacific coast since 2013. The disease, which causes lesions and arm loss, has severely impacted over 20 species, with the sunflower sea star losing approximately 90 percent of its population within five years. The breakthrough, published in Nature Ecology and Evolution, involved meticulously analyzing the coelomic fluid of sea stars, overcoming previous false leads that focused on dead tissue samples. Identifying the bacterium provides a crucial step for intervention, allowing scientists to test remaining sea stars, consider relocation or captive breeding, and investigate natural immunity or probiotic treatments. The recovery of sea star populations is vital for the Pacific ecosystem, as their decline led to an explosion in sea urchins, which subsequently decimated 95 percent of Northern California 's kelp forests.
Reuters
4 hours ago
- Reuters
Vertex's trial failure, scrapped study cloud pain drug push; shares slump
Aug 4 (Reuters) - Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage trial failure and will not start a study for expanded use of its approved pain drug, sending its shares down 14.4% after the bell. The company (VRTX.O), opens new tab has been diversifying into gene therapies and non-opioid painkillers as it looks to reduce its reliance on cystic fibrosis drugs, a market it dominates. Unlike opioids, which trigger the brain's reward centers, making them an addiction risk, Vertex's drugs block pain signals at the origin, providing a lucrative opportunity for the company. The next-generation non-opioid painkiller, called VX-993, reduced pain by 74.5 points over 48 hours, compared with 50.2 points in the placebo group, but the difference was not statistically significant, Vertex said. The company tested acute pain reduction in patients who had bunionectomy, a surgery to correct deformed bones of the big toe and foot. The drug was found to be generally safe, with most side effects being mild to moderate and no serious problems linked to the painkiller, the company said. Wall Street analysts and investors have been keenly watching the results of the trial, as Vertex seeks to expand beyond Journavx, its non-opioid approved by the U.S. Food and Drug Administration in January for acute pain. Separately, Vertex also said it would not start a study for Journavx to treat a type of nerve pain in the lower back and legs following discussion with the FDA. Leerink Partners analyst David Risinger said Vertex's pain portfolio updates were "disappointing," despite reporting second-quarter results that were above expectations. Vertex plans to prioritize testing of, and later seeking approval for, Journavx to treat a type of nerve pain in diabetic patients. It will also seek to secure approval for other types of nerve pain, the company said in its earnings press release.
